Tianjin University-AstraZeneca Joint Laboratory

Tianjin University-AstraZeneca Joint Laboratory

AstraZeneca
AstraZeneca partners with Tianjin University to improve manufacturing safety standards in China.
Continue reading
Healthy Heart Africa Capacity Building Activities

Healthy Heart Africa capacity building activities

AstraZeneca
AstraZeneca’s Healthy Heart Africa programme includes a range of capacity building activities to help reduce the burden of hypertension in Kenya.
Continue reading

Commitment to R&D for AMR

AstraZeneca, GSK, Johnson & Johnson, Merck & Co, Merck KGaA, Novartis, Pfizer, Roche, Sanofi
Nine companies have committed to R&D for antimicrobial resistance (AMR), signing the Davos Declaration by the Pharmaceutical, Biotechnology and Diagnostics Industries on Combating Antimicrobial Resistance.
Continue reading

Healthy Heart Africa Global Advisory Board and National Steering Committee

AstraZeneca
AstraZeneca has developed an internal governance structure for its Healthy Heart Africa programme, consisting of a Global Advisory Board and National Steering Committee.
Continue reading

Broad consideration of socio-economic factors when setting prices for a first-line heart disease medicine in multiple priority countries*

AstraZeneca
AstraZeneca considers five socio-economic factors when setting prices for a first-line heart disease medicine and targets 27% of priority countries. This is comparatively broad as the industry considers only two socio-economic factors per strategy, on average.
Continue reading
Young Health Programme

Young Health Programme

AstraZeneca
AstraZeneca’s Young Health Programme is a philanthropic capacity building programme focused on preventing non-communicable diseases among adolescents.
Continue reading

New pricing policy based on an analysis of populations’ ability to pay in key out-of-pocket markets

AstraZeneca
AstraZeneca has a new pricing policy for its respiratory and cardiovascular disease products in certain key out-of-pocket markets in scope, based on an ability-to-pay analysis.
Continue reading

Clarity in approach to IP management

AstraZeneca, GSK, Merck KGaA
AstraZeneca, GSK and Merck KGaA publicly disclose their patent filing and enforcement policy, and disclose or commit to disclose their patent status and licensing approach to support third party manufacture and/or supply of patented products.
Continue reading